

## PROVINCIAL FUNDING SUMMARY

### Pazopanib hydrochloride (Votrient) Resubmission for Metastatic Renal Cell Carcinoma

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: September 16, 2013

This information is current as of September 22, 2014. The use of this document is directed by [pCODR's Terms of Use](#).

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Sep 1, 2011	Advanced renal cell carcinoma; no prior systemic therapy (first-line therapy) or prior cytokines; ECOG performance status 0-2; and Compassionate Access Program (CAP) approval granted by BCCA.
AB	Funded	Mar 5, 2014	As an option in the first line treatment of advanced or metastatic clear cell renal cell carcinoma for patients with good performance status or if patients are unable to tolerate ongoing sunitinib. Not to be used after progression on sunitinib.
SK	Funded	Oct 29, 2012	First line treatment of patients with metastatic renal cell carcinoma (mRCC) with an ECOG performance status <2, or as an alternate treatment in patients who are unable to tolerate ongoing use of an effective dose of Sunitinib in the first line setting, or second line treatment in patients after cytokine failure or intolerance.
MB	Funded	Apr 16, 2014	As a first-line treatment for patients with advanced or metastatic clear cell renal cell carcinoma and good performance status.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
ON	Funded	Dec 17, 2013	<p>Initial requests: For first-line treatment of advanced or metastatic renal cell carcinoma of clear cell histology in patients with good performance status (ECOG 0-1). The approved dosage is 800mg once daily.</p> <p>Renewals will be considered for patients who have benefited from therapy (i.e. no disease progression) and are expected to continue to do so.</p> <p>Exclusion criteria: Funding for Votrient will not be approved for patients who demonstrate disease progression while on sunitinib, sorafenib, temsirolimus, everolimus or other drugs approved for treatment of metastatic renal cell carcinoma.</p> <p>Approval duration: 1 year for initial and renewals</p>
NS	Funded	May 20, 2014	<p>As a single agent first line treatment option for patients with documented evidence of histologically confirmed advanced or metastatic clear cell RCC who have an ECOG PS of 0 or 1.</p> <p>In any one patient, all of the following conditions must be met:</p> <ol style="list-style-type: none"> <li>1. Pazopanib may be a first line option.</li> <li>2. Pazopanib may not be used after another VEGF tyrosine kinase inhibitor as sequential therapy.</li> <li>3. In the event of significant toxicity, a switch to another VEGF tyrosine kinase inhibitor may be allowed.</li> </ol>
NB	Funded	Feb 10, 2014	<ol style="list-style-type: none"> <li>1. As a first-line treatment for patients with advanced or metastatic clear cell renal carcinoma and good performance status.</li> <li>2. For the treatment of advanced or metastatic renal cell (clear cell) carcinoma (mRCC) in patients who are unable to tolerate sunitinib and who have an ECOG performance status of 0 or 1.</li> </ol>
NL	Funded	Sep 1, 2014	<p>As a first-line treatment for patients with advanced or metastatic clear cell renal carcinoma and good performance status (ECOG 0-1).</p> <p>For patients with advanced or metastatic clear cell renal carcinoma who, based on the mutual assessment of the treating physician and the patient, are unable to tolerate ongoing use of an effective dose of sunitinib</p>

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
PEI	Funded	Apr 21, 2014	<ol style="list-style-type: none"><li>1. As a first-line treatment for patients with advanced or metastatic clear cell renal carcinoma and good performance status.</li><li>2. For the treatment of advanced or metastatic renal cell (clear cell) carcinoma (mRCC) in patients who are unable to tolerate sunitinib and who have an ECOG performance status of 0 or 1.</li></ol> Renewal criteria: Written confirmation that the patient has benefited from therapy and is expected to continue to do so.